Mucosal IL13RA2 expression predicts nonresponse to anti-TNF therapy in Crohn's disease.

ABSTRACT:

Background

Ileocolonic expression of IL13RA2 has been identified as a predictive marker for nonresponsiveness to infliximab (IFX) in patients with Crohn's disease (CD).

Aim

To validate the IL13RA2 biomarker, study its anti-TNF specificity and get a better understanding of the underlying biology driving its expression.

Methods

IL13RA2 mucosal expression was studied in a cohort of adalimumab and vedolizumab treated patients. To identify the upstream regulators of anti-TNF nonresponsiveness, weighted gene co-expression network analysis was applied on publicly available microarray data of IFX-treated patients. Selected serum proteins, including TNF, were measured prior to first IFX exposure and compared between healers and nonhealers.

Results

Increased mucosal IL13

SUBMITTER: Verstockt B 

PROVIDER: S-EPMC6849553 | biostudies-literature | 2019 Mar

REPOSITORIES: biostudies-literature